The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
Notice for selumetinib (AstraZeneca Pty Ltd)
Active ingredients
selumetinib
Sponsor
Date of review outcome
Lapse date
Type
Orphan drug
Dosage form(s)
Hard capsule
Indication
Treatment of Neurofibromatosis Type 1
Therapeutic area
Oncology